REGN, ILMN And CELG, Pushing Health Care Sector Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 7 points (0.0%) at 17,094 as of Thursday, July 24, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,609 issues advancing vs. 1,334 declining with 169 unchanged.

The Health Care sector currently is unchanged today versus the S&P 500, which is up 0.1%. On the negative front, top decliners within the sector include Varian Medical Systems ( VAR), down 6.1%, Jazz Pharmaceuticals ( JAZZ), down 2.1%, Novo Nordisk A/S ( NVO), down 1.5%, Stryker Corporation ( SYK), down 1.2% and Shire ( SHPG), down 0.8%. Top gainers within the sector include Intuitive Surgical ( ISRG), up 2.5%, Thermo Fisher Scientific ( TMO), up 1.1% and Express Scripts ( ESRX), up 0.7%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3. Regeneron Pharmaceuticals ( REGN) is one of the companies pushing the Health Care sector lower today. As of noon trading, Regeneron Pharmaceuticals is down $4.76 (-1.5%) to $305.51 on light volume. Thus far, 249,500 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 853,200 shares. The stock has ranged in price between $304.66-$311.50 after having opened the day at $310.40 as compared to the previous trading day's close of $310.27.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $30.3 billion and is part of the drugs industry. Shares are up 12.7% year-to-date as of the close of trading on Wednesday. Currently there are 6 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, poor profit margins and weak operating cash flow. Get the full Regeneron Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Illumina ( ILMN) is down $7.85 (-4.3%) to $172.79 on heavy volume. Thus far, 1.8 million shares of Illumina exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $170.80-$185.00 after having opened the day at $183.39 as compared to the previous trading day's close of $180.64.

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $22.0 billion and is part of the drugs industry. Shares are up 63.3% year-to-date as of the close of trading on Wednesday. Currently there are 9 analysts that rate Illumina a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, compelling growth in net income, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Illumina Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Celgene ( CELG) is down $3.21 (-3.6%) to $85.91 on heavy volume. Thus far, 5.4 million shares of Celgene exchanged hands as compared to its average daily volume of 5.2 million shares. The stock has ranged in price between $84.25-$87.76 after having opened the day at $87.26 as compared to the previous trading day's close of $89.12.

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. Celgene has a market cap of $68.9 billion and is part of the drugs industry. Shares are up 5.5% year-to-date as of the close of trading on Wednesday. Currently there are 18 analysts that rate Celgene a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Celgene as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, good cash flow from operations, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Celgene Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).
null

If you liked this article you might like

Handling Your Finances at Any Age: Cramer's 'Mad Money' Recap (Monday 2/12/18)

Handling Your Finances at Any Age: Cramer's 'Mad Money' Recap (Monday 2/12/18)

Volatility Reigns Supreme: Cramer's 'Mad Money' Recap (Thursday 2/8/18)

Volatility Reigns Supreme: Cramer's 'Mad Money' Recap (Thursday 2/8/18)

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Anthem, A.O. Smith, Tableau Software: 'Mad Money' Lightning Round

Anthem, A.O. Smith, Tableau Software: 'Mad Money' Lightning Round

Cramer Calls It a Market Reset: 'Mad Money' Recap (Monday 2/5/18)

Cramer Calls It a Market Reset: 'Mad Money' Recap (Monday 2/5/18)